{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T21:47:51Z","timestamp":1763329671161},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T00:00:00Z","timestamp":1479859200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2017,2]]},"DOI":"10.1007\/s00508-016-1124-4","type":"journal-article","created":{"date-parts":[[2016,11,23]],"date-time":"2016-11-23T09:58:04Z","timestamp":1479895084000},"page":"141-144","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia"],"prefix":"10.1007","volume":"129","author":[{"given":"Florian","family":"Huemer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dejaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Grabmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Melchardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Neureiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Egle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Greil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lukas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,23]]},"reference":[{"issue":"4","key":"1124_CR1","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ng1294-345","volume":"8","author":"KA McAllister","year":"1994","unstructured":"McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet. 1994;8(4):345\u201351.","journal-title":"Nat. Genet."},{"issue":"1","key":"1124_CR2","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1086\/513903","volume":"61","author":"JN Berg","year":"1997","unstructured":"Berg JN, Gallione CJ, Stenzel TT, et al. The activin receptor-like kinase 1 gene: genomic structure and mutations in hereditary hemorrhagic telangiectasia type 2. Am J Hum Genet. 1997;61(1):60\u20137.","journal-title":"Am. J. Hum. Genet."},{"issue":"4","key":"1124_CR3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/bjh.12377","volume":"162","author":"C Alderman","year":"2013","unstructured":"Alderman C, Corlett J, Cullis J. The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab. Br J Haematol. 2013;162(4):547\u20138.","journal-title":"Br. J. Haematol."},{"issue":"20","key":"1124_CR4","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1056\/NEJMc0901421","volume":"360","author":"P Bose","year":"2009","unstructured":"Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2009;360(20):2143\u20134.","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"1124_CR5","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1056\/NEJMc1012774","volume":"364","author":"BT Brinkerhoff","year":"2011","unstructured":"Brinkerhoff BT, Poetker DM, Choong NW. Long-term therapy with bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med. 2011;364(7):688\u20139.","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"1124_CR6","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","volume":"91","author":"CL Shovlin","year":"2000","unstructured":"Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91(1):66\u20137.","journal-title":"Am. J. Med. Genet."},{"issue":"4","key":"1124_CR7","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/lary.20818","volume":"120","author":"JB Hoag","year":"2010","unstructured":"Hoag JB, Terry P, Mitchell S, Reh D, Merlo CA. An epistaxis severity score for hereditary hemorrhagic telangiectasia. Laryngoscope. 2010;120(4):838\u201343.","journal-title":"Laryngoscope"},{"issue":"2","key":"1124_CR8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2500\/ar.2014.5.0091","volume":"5","author":"AB Thompson","year":"2014","unstructured":"Thompson AB, Ross DA, Berard P, Figueroa-Bodine J, Livada N, Richer SL. Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia. Allergy Rhinol (Providence). 2014;5(2):91\u20135.","journal-title":"Allergy Rhinol (Providence)"},{"issue":"3","key":"1124_CR9","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5045\/br.2014.49.3.192","volume":"49","author":"JW Wee","year":"2014","unstructured":"Wee JW, Jeon YW, Eun JY, Kim HJ, Bae SB, Lee KT. Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab. Blood Res. 2014;49(3):192\u20135.","journal-title":"Blood Res"},{"issue":"4","key":"1124_CR10","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2010.08481.x","volume":"152","author":"P Suppressa","year":"2011","unstructured":"Suppressa P, Liso A, Sabba C. Low dose intravenous bevacizumab for the treatment of anaemia in hereditary haemorrhagic telangiectasia. Br J Haematol. 2011;152(4):365.","journal-title":"Br. J. Haematol."},{"issue":"12","key":"1124_CR11","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1038\/ajg.2011.287","volume":"106","author":"G Lazaraki","year":"2011","unstructured":"Lazaraki G, Akriviadis E, Pilpilidis I, Parisi I, Tzilves D, Tarpangos A. Low dose of bevacizumab is safe and effective in preventing bleeding episodes in hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2011;106(12):2204\u20136.","journal-title":"Am. J. Gastroenterol."},{"key":"1124_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-016-2796-6","author":"F Droege","year":"2016","unstructured":"Droege F, Thangavelu K, Lang S, Geisthoff U. Improvement in hereditary hemorrhagic telangiectasia after treatment with the multi-kinase inhibitor Sunitinib. Ann Hematol. 2016; doi: 10.1007\/s00277-016-2796-6 .","journal-title":"Ann. Hematol."},{"issue":"Suppl","key":"1124_CR13","doi-asserted-by":"crossref","first-page":"abstr e14601","DOI":"10.1200\/jco.2015.33.15_suppl.e14601","volume":"33","author":"J Zhang","year":"2015","unstructured":"Zhang J, Cai Y, Hu H, Ling J, Xiao J, Deng Y. Bevacizumab, Aflibercept or Ramucirmab combined with chemotherapy as second-line treatment for metastatic colorectal cancer following progression with Bevacizumab in first-line therapy: A systematic review and indirect comparison. J\u00a0Clin Oncol. 2015;33(Suppl):abstr e14601.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1124_CR14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186\u201393.","journal-title":"Am J Kidney Dis"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-1124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00508-016-1124-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-016-1124-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,15]],"date-time":"2019-09-15T22:04:01Z","timestamp":1568585041000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00508-016-1124-4"}},"subtitle":["A\u00a0case report"],"short-title":[],"issued":{"date-parts":[[2016,11,23]]},"references-count":14,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2017,2]]}},"alternative-id":["1124"],"URL":"https:\/\/doi.org\/10.1007\/s00508-016-1124-4","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,23]]}}}